Project Grant K23HL188579
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $246,000 on August 14, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to analyze clinician-level variation in chest pain admission practices and its impact on downstream patient outcomes. The research will evaluate how emergency department clinicians' admitting tendencies for chest pain patients without acute coronary syndrome evidence affect subsequent testing...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $778,504 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate molecular mechanisms controlling lung capillary speciation, plasticity, and function during early postnatal development. The research examines how distinct subtypes of lung capillary endothelial cells—CAP1 and CAP2—contribute to alveolar formation and repair after injury during...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $200,880 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe metagenomic sequencing methods for diagnosing and predicting complications in lung transplant recipients. The project will develop metagenomic classifiers from bronchoalveolar lavage fluid to more accurately diagnose lower respiratory tract infection in...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,559,572 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the multiciliation cycle, a variant cell cycle mechanism that coordinates centriole biogenesis and ciliogenesis in multiciliated cells lining the mammalian airway. Multiciliated cells defend the lungs from inhaled pathogens and particulates but require...
- The National Heart Lung and Blood Institute, under the Department of Health and Human Services, awarded $369,089 to The Regents of the University of California, San Francisco on September 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837). The recipient is developing and evaluating computer-aided detection algorithms to support screening, diagnosis, and treatment of tuberculosis in children with and without HIV. The project addresses gaps in pediatric TB diagnosis, where...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $778,127 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL180797) to enhance lamellar body function via LRRK2 inhibition and reduce respiratory distress syndrome severity in preterm newborns. The research investigates leucine-rich repeat kinase 2 (LRRK2) inhibition as a novel therapeutic approach to enhance endogenous surfactant production in...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
The National Institutes of Health National Heart Lung and Blood Institute awarded the Regents of the University of California, San Francisco $168,025 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and pilot test an intervention for as-needed follow-up care for children with bronchiolitis discharged from emergency departments. The research addresses comparative effectiveness of two common post-discharge follow-up practices: routinely scheduled primary care clinic visits versus as-needed visits triggered only by clinical deterioration or new concerns. The project will refine an intervention for as-needed follow-up using input from multiple stakeholders and assess the feasibility of conducting a randomized trial comparing these two approaches. Current practice patterns result in substantial medical costs, parental work absences, and primary care clinic crowding, while observational evidence suggests routine follow-up visits may not prevent hospital revisits and can lead to potentially harmful treatments such as unnecessary antibiotics. The award is a Project Grant with a period of performance extending from September 1, 2026, to May 31, 2031. Work is performed in Oakland, California.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $168.0k | 8/12/26 |